European Union Approves Orkambi Use for Children 6-11 Years Old
Cystic Fibrosis, News
The European Commission has granted Vertex Pharmaceuticals an extension of the marketing authorization for Orkambi (lumacaftor/ivacaftor) to include children 6-11 years old who have cystic fibrosis (CF) caused by two copies ... Read more